Form 4: Recursion Pharmaceuticals COO Tina Marriott Reports Transaction
SEC Form 4 Filing
Tina Marriott, President and COO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations.
Summary
- On May 15, 2024, Tina Marriott, the President and COO of Recursion Pharmaceuticals, reported a transaction.
- The transaction involved the withholding of 9,998 shares of Class A Common Stock at a price of $10.01 per share.
- These shares were withheld by Recursion Pharmaceuticals to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units.
- Following the transaction, Marriott directly owns 533,233 shares of Class A Common Stock.
- Marriott also holds several stock options with varying exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and has a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders as it relates to tax obligations on existing equity compensation.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction |
| 05/17/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.